Yes , after this dose escalation part of the trial, I believe they will be pivoting to adaptive dosing. This means they will treat as needed rather than scheduled dosing. I guess the question is at what point in the treatment process do you begin to hold treatment until progression? Curative or other? We don't know those details yet, but the end goal of any therapy is OS.
Adaptive dosing may have the best OS vs scheduled dosing, altho it depends whether dosing heavily irrespective of RECIST/PSA response will have a longer term response or not.
CU6 Price at posting:
$3.68 Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)